Pharmaids Pharmaceuticals Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated April 7, 2026, pertains to the quarter ended March 31, 2026.

Regulatory Compliance Certificate

The certificate was issued by M/s Venture Capital and Corporate Investments Private Limited, which serves as the company's Registrar and Share Transfer Agent. The firm holds SEBI Registration No. INR000001203 and is authorized to handle the company's share transfer operations.

Dematerialization Compliance

The registrar's certificate confirms that all securities received for dematerialization have been properly processed according to regulatory requirements. The certificate specifically states that securities have been mutilated and cancelled after due verification, ensuring proper handling of physical share certificates.

Key compliance aspects covered include:

• Securities received for dematerialization have been mutilated and cancelled after verification
• Both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) have been updated as registered owners
• Updates completed within the mandatory 15-day timeframe from receipt of valid DRF and share certificates
• Details of securities furnished to relevant stock exchanges

Corporate Communication

The compliance certificate was signed by Prasanna Subramanya Bhat, Company Secretary and Compliance Officer of Pharmaids Pharmaceuticals Limited. The digital signature was applied on April 7, 2026, at 13:55:14 +05'30', confirming the authenticity of the submission.

The registrar's certificate, dated April 6, 2026, was addressed to the Company Secretary at the company's registered office in Brigade Rubix, Bangalore. This quarterly certification process ensures transparency in share dematerialization activities and maintains regulatory compliance with SEBI requirements.

Pharmaids Pharmaceuticals Limited has completed the divestment of its step-down subsidiary Siri Labvivo Diet Private Limited on March 27, 2026. The transaction was executed through the company's material subsidiary Adita Bio Sys Private Limited, which sold its shareholding in Siri Labvivo Diet Private Limited to an independent buyer.

Transaction Details

The sale agreement was finalized and completed on March 27, 2026, with the following key parameters:

Financial Impact and Contribution

Siri Labvivo Diet Private Limited's contribution to Pharmaids Pharmaceuticals' consolidated financials as on March 31, 2025, was relatively modest:

The subsidiary showed a negative networth position, indicating financial challenges that may have influenced the divestment decision.

Regulatory Compliance

The transaction has been disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Key compliance aspects include:

• The transaction does not fall under related party transaction category
• The buyer Mr. Shivakumar B G is not associated with the promoter or promoter group
• The sale is not part of any Scheme of Arrangement
• No slump sale provisions are applicable

Corporate Structure Impact

Following the completion of this divestment, Siri Labvivo Diet Private Limited has ceased to be a subsidiary of Adita Bio Sys Private Limited with effect from March 27, 2026. Consequently, it is no longer a step-down subsidiary of Pharmaids Pharmaceuticals Limited, simplifying the corporate structure and reducing the subsidiary network.

The transaction represents a strategic move by Pharmaids Pharmaceuticals to streamline its subsidiary portfolio, particularly given the negative networth contribution of the divested entity. The company has fulfilled all regulatory disclosure requirements and confirmed the arm's length nature of the transaction with an independent buyer.